BACKGROUND: We have demonstrated that postshock administration of suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, can significantly improve early survival in a highly lethal model of hemorrhagic shock. As the primary insult in hemorrhagic shock is cellular hypoxia, and transcription factor hypoxia-inducible factor-1α (HIF-1α) controls proinflammatory gene expression in macrophages, we hypothesized that SAHA would attenuate the HIF-1α associated proinflammatory pathway in a hypoxic macrophage model. METHODS: Mouse macrophages were exposed to hypoxic conditions (0.5% O2, 10% CO2, and 89.5% N2) at 37°C in the presence or absence of SAHA (10 μmol/L). The cells and culture medium were harvested at 1 hour, 4 hours, and 8 hours. Sham (no hypoxia, no SAHA) served as a control. Western blots were performed to assess protein levels of prolyl hydroxylase 2 (PHD2), HIF-1α, and inducible nitric oxide synthase (iNOS) in the cells. Colorimetric biochemical assay and enzyme-linked immunosorbent assay were used to analyze the release of nitric oxide (NO) and secretion of tumor necrosis factor α (TNF-α), respectively, in the cell culture medium. RESULTS: Hypoxia significantly increased cellular level of HIF-1α (1 hour and 4 hours), gene transcription of iNOS (4 hours and 8 hours), iNOS protein (8 hours), NO production (8 hours), and TNF-α secretion (4 hours and 8 hours). SAHA treatment attenuated all of the above hypoxia-induced alterations in the macrophages. In addition, SAHA treatment significantly increased cellular level of PHD2, one of the upstream negative regulators of HIF-1α, at 1 hour. CONCLUSIONS: Treatment with SAHA attenuates hypoxia-HIF-1α-inflammatory pathway in macrophages and suppresses hypoxia-induced release of proinflammatory NO and TNF-α. SAHA also causes an early increase in cellular PHD2, which provides, at least in part, a new explanation for the decrease in the HIF-1α protein levels.
BACKGROUND: We have demonstrated that postshock administration of suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, can significantly improve early survival in a highly lethal model of hemorrhagic shock. As the primary insult in hemorrhagic shock is cellular hypoxia, and transcription factor hypoxia-inducible factor-1α (HIF-1α) controls proinflammatory gene expression in macrophages, we hypothesized that SAHA would attenuate the HIF-1α associated proinflammatory pathway in a hypoxic macrophage model. METHODS:Mouse macrophages were exposed to hypoxic conditions (0.5% O2, 10% CO2, and 89.5% N2) at 37°C in the presence or absence of SAHA (10 μmol/L). The cells and culture medium were harvested at 1 hour, 4 hours, and 8 hours. Sham (no hypoxia, no SAHA) served as a control. Western blots were performed to assess protein levels of prolyl hydroxylase 2 (PHD2), HIF-1α, and inducible nitric oxide synthase (iNOS) in the cells. Colorimetric biochemical assay and enzyme-linked immunosorbent assay were used to analyze the release of nitric oxide (NO) and secretion of tumor necrosis factor α (TNF-α), respectively, in the cell culture medium. RESULTS:Hypoxia significantly increased cellular level of HIF-1α (1 hour and 4 hours), gene transcription of iNOS (4 hours and 8 hours), iNOS protein (8 hours), NO production (8 hours), and TNF-α secretion (4 hours and 8 hours). SAHA treatment attenuated all of the above hypoxia-induced alterations in the macrophages. In addition, SAHA treatment significantly increased cellular level of PHD2, one of the upstream negative regulators of HIF-1α, at 1 hour. CONCLUSIONS: Treatment with SAHA attenuates hypoxia-HIF-1α-inflammatory pathway in macrophages and suppresses hypoxia-induced release of proinflammatory NO and TNF-α. SAHA also causes an early increase in cellular PHD2, which provides, at least in part, a new explanation for the decrease in the HIF-1α protein levels.
Authors: Eoin P Cummins; Edurne Berra; Katrina M Comerford; Amandine Ginouves; Kathleen T Fitzgerald; Fergal Seeballuck; Catherine Godson; Jens E Nielsen; Paul Moynagh; Jacques Pouyssegur; Cormac T Taylor Journal: Proc Natl Acad Sci U S A Date: 2006-11-17 Impact factor: 11.205
Authors: Yongqing Li; Baoling Liu; Hang Zhao; Elizabeth A Sailhamer; Eugene Y Fukudome; Xiaobo Zhang; Tareq Kheirbek; Robert A Finkelstein; George C Velmahos; Marc deMoya; Charles A Hales; Hasan B Alam Journal: Shock Date: 2009-11 Impact factor: 3.454
Authors: Hasan B Alam; Fahad Shuja; Muhammad U Butt; Michael Duggan; Yongqing Li; Nikolaos Zacharias; Eugene Y Fukudome; Baoling Liu; Marc Demoya; George C Velmahos Journal: Surgery Date: 2009-06-25 Impact factor: 3.982
Authors: Christian Shults; Elizabeth A Sailhamer; Yongqing Li; Baoling Liu; Malek Tabbara; Muhammad Umar Butt; Fahad Shuja; Marc Demoya; George Velmahos; Hasan B Alam Journal: J Trauma Date: 2008-03
Authors: Elizabeth A Sailhamer; Yongqing Li; Eleanor J Smith; Fahad Shuja; Christian Shults; Baoling Liu; Chad Soupir; Marc deMoya; George Velmahos; Hasan B Alam Journal: Surgery Date: 2008-08 Impact factor: 3.982
Authors: Hsin-Yu Fang; Russell Hughes; Craig Murdoch; Seth B Coffelt; Subhra K Biswas; Adrian L Harris; Randall S Johnson; Hongxia Z Imityaz; M Celeste Simon; Erik Fredlund; Florian R Greten; Jordi Rius; Claire E Lewis Journal: Blood Date: 2009-05-19 Impact factor: 22.113
Authors: Ting Zhao; Yongqing Li; Baoling Liu; Zhengcai Liu; Wei Chong; Xiuzhen Duan; Danielle K Deperalta; George C Velmahos; Hasan B Alam Journal: Surgery Date: 2013-08 Impact factor: 3.982
Authors: Ting Zhao; Yongqing Li; Baoling Liu; Erxi Wu; Martin Sillesen; George C Velmahos; Ihab Halaweish; Hasan B Alam Journal: Surgery Date: 2014-06-21 Impact factor: 3.982
Authors: Peter J Bruhn; Vahagn C Nikolian; Ihab Halaweish; Zhigang Chang; Martin Sillesen; Baoling Liu; Yongqing Li; Hasan B Alam Journal: J Trauma Acute Care Surg Date: 2018-02 Impact factor: 3.313